March 9, 2020 10:00 AM EDTUpdated 01:14 PM

With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra

Natalie Grover

Reporter

Mixed data from previous study readouts on its drug for short-term dry eye relief precipitated a rejection from the FDA, leaving Kala Pharmaceuticals’ fate in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra

Natalie Grover

Reporter

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

With pos­i­tive key tri­al, Kala Phar­ma's dry eye drug Ey­su­vis em­u­lates ap­proval path set by Xi­idra

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Soleno’s rare pediatric disease drug faces PDUFA delay by three months